本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Milestone Pharmaceuticals Inc.

1.88
-0.0100-0.53%
盘前1.920.0400+2.13%09:00 EDT
成交量:145.60万
成交额:273.85万
市值:1.60亿
市盈率:-2.24
高:1.93
开:1.91
低:1.86
收:1.89
52周最高:2.75
52周最低:0.6254
股本:8,499.43万
流通股本:7,881.45万
量比:0.88
换手率:1.85%
股息:- -
股息率:- -
每股收益(TTM):-0.8376
每股收益(LYR):-0.6674
净资产收益率:-780.29%
总资产收益率:-50.33%
市净率:-9.00
市盈率(LYR):-2.82

数据加载中...

2021/03/29

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/03/29

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/02/16

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/21

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/11

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/12/16

SEC问询函

CORRESP [Cover] - Correspondence
2020/11/13

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/10/26

重要事件披露

8-K - Current report
2020/10/23

[修订]年度报告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2020/09/22

重要事件披露

8-K - Current report
2020/08/12

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/08/03

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/07/29

重要事件披露

8-K - Current report
2020/07/23

重要事件披露

8-K - Current report